Emergence of resistance against direct acting antivirals in chronic HCV patients: A real-world study

Majid, Abdul; Khan, Sanaullah; Siraj, Sami; Haleem, Sumbal; Haq, Najib ul; Ullah, Riaz; Ali, Essam A.; Mustafa, Adeela; Hussain, Hidayat; Sohaib, Muhammad

doi:10.1016/j.sjbs.2021.12.044

Cited by 1 publication

(1 citation statement)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However there was no association of INF experience in past, age or gender. [129] Along with several contrinuting factors the most widely evaluated one is resitance associated substitutions(RASs) which are detected in these treatment failure cases. Saima Mushtaq in collaboration with Rawalpindi Medical University evaluated that A62S/T, A30K and Y93H are the most commonly demonstrated RASs in GCV genotype 3 patients from Pakistan.…”

Section: Experienced Noncirrhotic Cld and Compensated Cirrhosismentioning

confidence: 99%

An Update on National Consensus Practice Guidelines for the Treatment of Hepatitis C & Literature Review in Epidemiology of Hepatitis C in Pakistan - 2022

Syed,

Umar,

Khaar

et al. 2024

JRMC

View full text Add to dashboard Cite

Hepatitis C is a global health problem affecting around 58 million people worldwide and killing almost 0.29 million in on one year [1]. The world has united to fight against this lethal disease in 2016 with a moto to eliminate hepatitis by 2030. To achieve this goal WHO’s World Health Assembly has set some targets and individual countries have developed their own strategies to achieve those targets [2]. Pakistan has the 2nd highest prevalence of hepatitis C in the world with 5.8% viremia positive patients [3]. Pakistan is amongst the few countries that have been assisted by the Center for Disease Control and Prevention(CDC) to prevent and control Hepatitis[4]. With the availability of Direct Acting Antivirals(DAAs), the whole paradigm of treatment of hepatitis C has changed not only globally but also in Pakistan. However, the patients in Pakistan are unable to gain access to the latest DAAs at the pace, as they are available globally. International guidelines are being updated on regular basis as per global evidence, recommending such combinations which are not readily available to many parts of the world. Hence there is a dire need to develop national guidelines, keeping in consideration the efficacy of the drugs as well as their availability, in the broader canvas of achieving the targets of eliminating Hepatitis set by WHO. In this context, our consensus guidelines are an effort to fill the gap created because of upgraded scientific evidence and possible combinations available in our part of the world. Furthermore, quite some good research and evidence has also been shared in the literature from Pakistan during last five years (2016-2021). Hence a literature review has also been carried out to update our own epidemiologic data, risk factors and treatment responses to Hepatitis C in Pakistan.

show abstract

Section: Experienced Noncirrhotic Cld and Compensated Cirrhosismentioning

confidence: 99%